NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,537.81 +223.95 (+1.22%) CRUDE OIL
79.45 +0.46 (+0.58%) GOLD FUTURES
2,344.10 +21.80 (+0.94%) DOW
39,369.11 +312.72 (+0.80%) Bitcoin GBP
49,719.67 -182.93 (-0.37%)
argenx SE (0QW0.IL)
- GlobeNewswire
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announc
- Zacks
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Globe Newswire
argenx announces results of Annual General Meeting of Shareholders
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today. All items on the agenda received a majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). As part of the approved resolutions: The Company's annual report and annual accounts for t
